表紙
市場調査レポート

再発寛解型多発性硬化症(RRMS):パイプライン製品の分析

Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 251610
出版日 ページ情報 英文 204 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
再発寛解型多発性硬化症(RRMS):パイプライン製品の分析 Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2016
出版日: 2016年04月20日 ページ情報: 英文 204 Pages
概要

再発寛解型多発性硬化症(RRMS)とは多発性硬化症(MS)のもっとも一般的な形態であり、炎症活動(の再発)が明確に見られる疾患です。急性炎症の発症時には、過去の症状が悪化し、新しい症状も現れる場合もあります。再発とは24時間以上持続する活動性の炎症とそれに伴った症状をいいます。刺痛、しびれ感、複視、 疲労感、尿意切迫、筋力低下などの症状があり、コルチコステロイドや免疫グロブリン療法などの治療法があります。

当レポートでは、世界における再発寛解型多発性硬化症(RRMS)治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

再発寛解型多発性硬化症(RRMS)の概要

治療薬の開発

  • 再発寛解型多発性硬化症(RRMS)向けパイプライン製品:概要
  • 再発寛解型多発性硬化症(RRMS)向けパイプライン製品:比較分析

再発寛解型多発性硬化症(RRMS):開発中の治療薬:企業別

再発寛解型多発性硬化症(RRMS):調査中の治療薬:大学・研究機関別

再発寛解型多発性硬化症(RRMS):パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

再発寛解型多発性硬化症(RRMS):開発中の製品:企業別

再発寛解型多発性硬化症(RRMS):調査中の製品:大学・研究機関別

再発寛解型多発性硬化症(RRMS):治療薬開発に従事している企業

  • AB Science SA
  • AbbVie Inc.
  • Actelion Ltd
  • Alkermes Plc
  • Amarna Therapeutics B.V.
  • Antisense Therapeutics Limited
  • Biocon Limited
  • Biogen, Inc.
  • Cognosci, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Forward Pharma A/S
  • GeNeuro SA
  • GlaxoSmithKline Plc
  • Iltoo Pharma
  • InteKrin Therapeutics, Inc.
  • Mapi Pharma Ltd.
  • MedImmune, LLC
  • Merck KGaA
  • 田辺三菱製薬
  • Neurotec Pharma SL
  • Novartis AG
  • Octapharma AG
  • Opexa Therapeutics, Inc.
  • RedHill Biopharma Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Xenetic Biosciences (UK) Limited
  • Zydus Cadila Healthcare Limited

再発寛解型多発性硬化症(RRMS):治療薬の評価

  • 単剤療法用の治療薬
  • 併用療法用の治療薬
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (クラリスロマイシン + クロファジミン + リファブチン)
  • アルデスロイキン
  • ALKS-8700
  • amiselimod hydrochloride
  • ATL-1102
  • AZ-17
  • 再発寛解型多発性硬化症(RRMS)の細胞免疫療法
  • クラドリビン
  • COG-133
  • ダクリズマブ
  • ジアゾキシド
  • フマル酸ジメチル
  • 再発寛解型多発性硬化症(RRMS)の遺伝子療法
  • 酢酸グラチマー ER
  • GNbAC-1
  • GSK-239512
  • グアナベンズ
  • HR-411
  • ヒドララジン
  • IB-MS
  • imilecleucel-t
  • 免疫グロブリン(ヒト)
  • inebilizumab
  • INT-131
  • インターフェロンベータ-1b
  • インターフェロンベータ-1b
  • itolizumab
  • laquinimod sodium
  • M-2736
  • masitinib
  • MyeloXen
  • ocrelizumab
  • ofatumumab
  • opicinumab
  • Pegylated Interferon-Beta-1b
  • ponesimod
  • siponimod
  • Small Molecule to Target CTLA4 and IFNGR for RRMS
  • Xemys
    • 製品概要
    • 作用機序
    • R&Dの進捗

最新のパイプライン動向

休止中のプロジェクト

開発中止の製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC7831IDB

Summary

Global Markets Direct's, 'Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2016', provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Relapsing Remitting Multiple Sclerosis (RRMS)
  • The report reviews pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Relapsing Remitting Multiple Sclerosis (RRMS) therapeutics and enlists all their major and minor projects
  • The report assesses Relapsing Remitting Multiple Sclerosis (RRMS) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Relapsing Remitting Multiple Sclerosis (RRMS)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Relapsing Remitting Multiple Sclerosis (RRMS) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Relapsing Remitting Multiple Sclerosis (RRMS) Overview
  • Therapeutics Development
    • Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Overview
    • Pipeline Products for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Development by Companies
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics under Investigation by Universities/Institutes
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Development by Companies
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Products under Investigation by Universities/Institutes
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Companies Involved in Therapeutics Development
    • AB Science SA
    • AbbVie Inc.
    • Actelion Ltd
    • Alkermes Plc
    • Amarna Therapeutics B.V.
    • Antisense Therapeutics Limited
    • Biocon Limited
    • Biogen, Inc.
    • Cognosci, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Forward Pharma A/S
    • GeNeuro SA
    • GlaxoSmithKline Plc
    • Iltoo Pharma
    • InteKrin Therapeutics, Inc.
    • Mapi Pharma Ltd.
    • MedImmune, LLC
    • Merck KGaA
    • Mitsubishi Tanabe Pharma Corporation
    • Neurotec Pharma SL
    • Novartis AG
    • Octapharma AG
    • Opexa Therapeutics, Inc.
    • RedHill Biopharma Ltd.
    • Teva Pharmaceutical Industries Ltd.
    • Xenetic Biosciences (UK) Limited
    • Zydus Cadila Healthcare Limited
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (clarithromycin + clofazimine + rifabutin) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • aldesleukin - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ALKS-8700 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • amiselimod hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ATL-1102 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AZ-17 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cellular Immunotherapy for Relapsing Remitting Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cladribine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • COG-133 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • daclizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diazoxide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • dimethyl fumarate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Gene Therapy for Relapsing and Remitting Multiple Sclerosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • glatiramer acetate ER - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GNbAC-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GSK-239512 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Guanabenz - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HR-411 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hydralazine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • IB-MS - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • imilecleucel-t - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • immune globulin (human) - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • inebilizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • INT-131 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon beta-1b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • interferon beta-1b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • itolizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • laquinimod sodium - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • M-2736 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • masitinib - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MyeloXen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ocrelizumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ofatumumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • opicinumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Pegylated Interferon-Beta-1b - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ponesimod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • siponimod - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Target CTLA4 and IFNGR for RRMS - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Xemys - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Recent Pipeline Updates
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Product Development Milestones
    • Featured News & Press Releases
      • Apr 12, 2016: Teva to Present Data on laquinimod at 68th AAN Annual Meeting
      • Mar 31, 2016: RedHill Announces Interim Results from Phase IIa PoC Study Supporting Therapeutic Potential of RHB-104 in Multiple Sclerosis
      • Oct 08, 2015: Results from ZINBRYTA (Daclizumab High-Yield Process) Phase 3 DECIDE Study Highlighting Efficacy Compared to Interferon Beta-1a Published in the New England Journal of Medicine and Presented at ECTRIMS
      • Oct 01, 2015: Biogen To Present Phase 3 Data On ZINBRYTA at ECTRIMS Congress
      • Jun 25, 2015: Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial
      • Jun 09, 2015: RedHill Biopharma Announces Completion of Patient Enrollment in the Phase IIa Study of RHB-104 for Multiple Sclerosis
      • Feb 26, 2015: Abbvie's Ongoing Research In Neuroscience And Oncology On ZINBRYTA Will Be Featured At The 2015 American Academy Of Neurology Annual Meeting
      • Dec 17, 2014: First Patient Treated in Mapi Pharma's Phase IIa Clinical Trial of GA Depot for Relapsing Remitting Multiple Sclerosis
      • Sep 12, 2014: Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA (Daclizumab High-Yield Process)
      • Sep 12, 2014: Teva Presents New Clinical Safety Data in RRMS Patients Treated with Laquinimod for Two or More Years at Joint ACTRIMS-ECTRIMS Meeting
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2016
  • Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AB Science SA, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by AbbVie Inc., H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Actelion Ltd, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Alkermes Plc, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Amarna Therapeutics B.V., H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Antisense Therapeutics Limited, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biocon Limited, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Biogen, Inc., H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Cognosci, Inc., H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Forward Pharma A/S, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GeNeuro SA, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Iltoo Pharma, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by InteKrin Therapeutics, Inc., H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mapi Pharma Ltd., H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by MedImmune, LLC, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Merck KGaA, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Neurotec Pharma SL, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Novartis AG, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Octapharma AG, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Opexa Therapeutics, Inc., H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by RedHill Biopharma Ltd., H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Xenetic Biosciences (UK) Limited, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) Therapeutics - Recent Pipeline Updates, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects, H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Dormant Projects (Contd..1), H1 2016
  • Relapsing Remitting Multiple Sclerosis (RRMS) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS), H1 2016
  • Number of Products under Development for Relapsing Remitting Multiple Sclerosis (RRMS) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top